OPTHEA LTD-SPON ADR (OPT)
US68386J2087 - ADR
Taking everything into account, OPT scores 2 out of 10 in our fundamental rating. OPT was compared to 588 industry peers in the Biotechnology industry. OPT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, OPT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year OPT has reported negative net income.
In the past year OPT has reported a negative cash flow from operations.
OPT had negative earnings in each of the past 5 years.
OPT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
OPT's Return On Assets of -97.06% is on the low side compared to the rest of the industry. OPT is outperformed by 76.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.06% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-110.61%
ROA(5y)-81.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for OPT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OPT has been increased compared to 1 year ago.
Compared to 5 years ago, OPT has more shares outstanding
OPT has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -5.24, we must say that OPT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.24, OPT is not doing good in the industry: 63.65% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.24 |
ROIC/WACCN/A
WACC7.55%
2.3 Liquidity
A Current Ratio of 5.10 indicates that OPT has no problem at all paying its short term obligations.
OPT has a Current ratio of 5.10. This is comparable to the rest of the industry: OPT outperforms 55.46% of its industry peers.
OPT has a Quick Ratio of 5.10. This indicates that OPT is financially healthy and has no problem in meeting its short term obligations.
OPT has a Quick ratio of 5.10. This is comparable to the rest of the industry: OPT outperforms 56.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.1 | ||
| Quick Ratio | 5.1 |
3. Growth
3.1 Past
OPT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.50%.
Looking at the last year, OPT shows a very negative growth in Revenue. The Revenue has decreased by -17.99% in the last year.
The Revenue for OPT have been decreasing by -32.58% on average. This is quite bad
EPS 1Y (TTM)6.5%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q30.14%
Revenue 1Y (TTM)-17.99%
Revenue growth 3Y22.44%
Revenue growth 5Y-32.58%
Revenue growth Q2Q16.68%
3.2 Future
OPT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.33% yearly.
Based on estimates for the next years, OPT will show a very strong growth in Revenue. The Revenue will grow by 369.83% on average per year.
EPS Next Y23.56%
EPS Next 2Y23.61%
EPS Next 3Y21.51%
EPS Next 5Y15.33%
Revenue Next Year10.07%
Revenue Next 2Y4.92%
Revenue Next 3Y4.56%
Revenue Next 5Y369.83%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
OPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OPT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as OPT's earnings are expected to grow with 21.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.61%
EPS Next 3Y21.51%
5. Dividend
5.1 Amount
No dividends for OPT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OPTHEA LTD-SPON ADR
NASDAQ:OPT (4/29/2024, 11:59:20 AM)
3.29
-0.11 (-3.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap272.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.06% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.1 | ||
| Quick Ratio | 5.1 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)6.5%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y23.56%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-17.99%
Revenue growth 3Y22.44%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y